vedolizumab
Preventing Postoperative CD Recurrence and Predicting Recurrence Risk After Stopping Infliximab
One of my long-standing research interests is how to prevent CD recurrence after surgical resection.
FEBRUARY 21, 2025
Approach to Older Adults With Moderate To Severe Crohn’s Disease
The incidence and prevalence of inflammatory bowel disease are rising worldwide, particularly in older adults.
DECEMBER 23, 2024
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
IBD Clinical Trials at a Crossroads
Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.
OCTOBER 22, 2024
The ABCs of Optimizing Drug Sequencing for IBD
The number of inflammatory bowel disease treatment options with different mechanisms of action has exploded over ...
OCTOBER 13, 2024
Combination Advanced Therapy in the Treatment of Inflammatory Bowel Disease
The development of effective biologics and small molecule targeted therapies has revolutionized the treatment of ...
SEPTEMBER 5, 2024
Study Looks at Infection Risk in Older IBD Patients on Immunosuppressive Therapies
Older adults represent a growing segment of patients with IBD, and several unique factors should be considered when ...
AUGUST 30, 2024
AGA Issues Guideline on Management of Pouchitis
The American Gastroenterological Association recently published a guideline on the management of pouchitis and ...
JULY 31, 2024
Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s
In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...
JUNE 19, 2024
Treating Patients With Inflammatory Bowel Disease and Obesity
An estimated 41% of the US population is obese, including 22% of individuals aged 12 to 19 years, while nearly 1 of ...
MAY 10, 2024
Early Data From VERDICT Trial Show UC Disease Clearance at 16 Weeks With Vedolizumab
More than 40% of patients with ulcerative colitis taking vedolizumab achieved disease clearance at 16 weeks of ...
MAY 6, 2024
FDA Grants New Indication for Subcutaneous Entyvio
The FDA expanded the indication for subcutaneous administration of vedolizumab to certain patients with ...
APRIL 22, 2024
